TITLE

Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol

AUTHOR(S)
Rubio-Valera, Maria; Serrano-Blanco, Antoni; Travé, Pere; Teresa Peñarrubia-María, M.; Ruiz, Mar; Pujol, Marian March
PUB. DATE
January 2009
SOURCE
BMC Public Health;2009, Vol. 9 Issue 1, p284
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and cost-effectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196
ACCESSION #
44171666

 

Related Articles

  • Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Capoccia, Kam L.; Boudreau, Denise M.; Blough, David K.; Ellsworth, Allan J.; Clark, Dave R.; Stevens, Nancy G.; Katon, Wayne J.; Sullivan, Sean D. // American Journal of Health-System Pharmacy;2/15/2004, Vol. 61 Issue 4, p364 

    The impact of pharmacist interventions on the care and outcomes of patients with depression in a primary care setting was evaluated. Patients diagnosed with a new episode of depression and started on antidepressant medications were randomized to enhanced care (EC) or usual care (UC) for one...

  • Analysis of quality of life data in controlled clinical trials. Royston, Patrick // Statistical Methods in Medical Research;Feb2002, Vol. 11 Issue 1, p1 

    Editorial. Comments on the analysis of quality of life (QL) data in controlled clinical trials in London, England. Development of instruments to measure QL; Lecturers of the workshop on QL; Influence of QL data on government-level decisions about health.

  • Measuring Quality of Life in Clinical Trials: A Taxonomy and Review.  // JAMA: Journal of the American Medical Association;1/12/90, Vol. 263 Issue 2, p301 

    Presents an abstract of the study 'Measuring Quality of Life in Clinical Trials,' published in an issue of the 'Canadian Medical Association Journal.'

  • Pharmaceutical care - impact on quality of life in patients with type 2 diabetes: a review. Krass, Ines; Dhippayom, Teerapon // Clinical Audit;2013, Vol. 5, p17 

    Type 2 diabetes mellitus (T2DM), a chronic disorder now reaching epidemic proportions, imposes a huge burden on individuals and health care systems. In recent years, pharmacists, highly trained health care professionals with expertise in medicines, have sought to develop an expanded role in...

  • Black-Box Warnings.  // Antidepressants & Social Anxiety: A Pill for Shyness?;2007, p71 

    The article reports on the result of various studies which shows that the some children who are treated with antidepressants can experience increased suicidal thoughts and behaviors. The study, which involved nine different antidepressants, found out that none of the respondents committed...

  • Amitriptyline: still efficacious, but at what cost? Thompson, Chris // British Journal of Psychiatry;Feb2001, Vol. 178, p99 

    The article focuses the examination concerning efficacy of the antidepressant drug Amitriptyline. Researchers have claimed that Amitriptyline is still the leading antidepressant. Based on the randomized controlled trials (RCT), the drug has a small efficacy advantage over all other...

  • Quality of life measures in health care. II: Design, analysis, and interpretation. Fletcher, Astrid; Gore, Sheila; Jones, David; Fitzpatrick, Ray; Spiegelhalter, David; Cox, David // BMJ: British Medical Journal (International Edition);11/7/92, Vol. 305 Issue 6862, p1145 

    Part II. Focuses on the design, analysis and interpretation of studies using quality of life measures in clinical trials in Great Britain. Influence of choice of dimension by the severity and nature of the disease; Selection of quality of life instruments; Considerations in the administration...

  • The effects of infliximab maintenance therapy on health-related quality of life Feagan, Brian G.; Yan, Songkai; Bala, Mohan; Bao, Weihang; Lichtenstein, Gary R. // American Journal of Gastroenterology;Oct2003, Vol. 98 Issue 10, p2232 

    : ObjectivesThe ACCENT I study evaluated the long term effects of infliximab as maintenance therapy for patients with Crohn''s disease. Health-related quality of life (HRQL) was also assessed in the trial.: MethodsIn ACCENT I, a total of 573 patients received a single infusion of 5 mg/kg...

  • Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome. Julious, S A; Campbell, M J; Walker, S J; George, S L; Machin, D // British Journal of Cancer;10/1/2000, Vol. 83 Issue 7, p959 

    Health Related Quality of Life (HRQoL) instruments are increasingly important in evaluating health care, especially in cancer trials. When planning a trial, one essential step is the calculation of a sample size, which will allow a reasonable chance (power) of detecting a pre-specified...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics